Vanda Pharmaceuticals (VNDA) Deferred Taxes (2010 - 2025)

Vanda Pharmaceuticals has reported Deferred Taxes for 8 years, with the latest figure at $103.2 million in Q4 2025.

• Quarterly Deferred Taxes rose 5491.12% year-over-year to $103.2 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $89.2 million (up 735.93% YoY) and the FY2025 annual result came in at $81.4 million, up 1356.45% from the prior year.
• Deferred Taxes advanced to $103.2 million in Q4 2025 per VNDA's latest filing, from -$6.0 million in the prior quarter.
• Over five years, Deferred Taxes peaked at $103.2 million in Q4 2025 and troughed at -$8.0 million in Q2 2025.
• A 5-year average of $4.1 million and a median of $85500.0 in 2022 frame the typical range for Deferred Taxes.
• The widest YoY moves for Deferred Taxes: up 5491.12% in 2025, down 3069.51% in 2025.
• Over 5 years, Deferred Taxes stood at $1.3 million in 2021, then plunged by 68.24% to $417000.0 in 2022, then tumbled by 1894.72% to -$7.5 million in 2023, then surged by 74.43% to -$1.9 million in 2024, then jumped by 5491.12% to $103.2 million in 2025.
• According to Business Quant data, Deferred Taxes over the past three periods registered $103.2 million, -$6.0 million, and -$8.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.